Antiseptic-Tolerant Pediococcus Strains for Oral Microbiota Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral antiseptics, such as chlorhexidine and triclosan, are effective but can disrupt the natural oral microbiota, leading to dysbiosis and side effects like mucosal irritation and tooth staining, while probiotics like L. reuteri have shown mixed results in treating periodontal diseases.
Innovation Solution
The use of Pediococcus strains that are tolerant to antiseptics, allowing them to be administered alongside, thereby protecting against opportunistic pathogens and maintaining a healthy oral microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiseptics such as chlorhexidine and triclosan are used to treat periodontal diseases, then antimicrobial effectiveness is improved, but disruption of oral microbiota and side effects worsen
Solution Approach 1:
The patent introduces lactic acid bacteria as intermediary organisms that mediate between the antiseptic treatment and the oral microbiota. These bacteria tolerate the antiseptic environment while producing beneficial substances that protect against opportunistic pathogens, thus preserving the balance of oral microbiota during antiseptic therapy
Solution Approach 2:
The patent converts the potentially harmful effect of antiseptics on oral microbiota into a benefit by selecting lactic acid bacteria strains that not only tolerate the antiseptic but also thrive in this environment. These strains transform the stressor (antiseptic) into a selective pressure that favors beneficial bacteria, thereby converting the harmful disruption into enhanced microbial balance
2Object-generated harmful factors
If probiotics are used to treat periodontal diseases, then restoration of oral microbiota is improved, but treatment effectiveness varies
Solution Approach 1:
The patent applies parameter changes by selecting specific lactic acid bacteria strains with defined tolerance characteristics to antiseptics. Instead of using generic probiotics, the invention specifies strains that have been characterized for their ability to tolerate common antiseptics while maintaining probiotic benefits, thereby improving treatment reliability
Solution Approach 2:
The patent creates a composite approach by combining lactic acid bacteria with antiseptic agents in a synergistic formulation. This composite system leverages the antimicrobial properties of both components, where the bacteria tolerate the antiseptic and work together to provide enhanced protection against periodontal pathogens
Data Source
AI summary
The present invention relates to lactic acid bacteria strains with the ability to tolerate antiseptics. The lactic acid bacteria strains have further the capacity to antagonize the growth of oral pathogens. Particularly, the lactic acid bacteria having these features belong to Pediococcus genus, more particularly to Pediococcus acidilactici species. Thus, the strains of the present invention are useful for compositions and products in the field of personal care, and 10 particularly, for oral care, as well as, for pharmaceutical products.